|
Aug 27
|
Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
|
|
Jul 29
|
Clearside Biomedical’s Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of ARCATUS® for Suprachoroidal Use in Uveitic Macular Edema Patients in China
|
|
Jul 11
|
Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board
|
|
Jun 27
|
Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery
|
|
May 10
|
Q1 2024 Clearside Biomedical Inc Earnings Call
|
|
May 10
|
Clearside Biomedical, Inc. (NASDAQ:CLSD) Q1 2024 Earnings Call Transcript
|
|
May 9
|
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 9
|
Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update
|
|
May 8
|
Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference
|
|
Apr 30
|
Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024
|
|
Apr 16
|
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
|
|
Apr 2
|
Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
|
|
Mar 18
|
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
|
|
Mar 14
|
Clearside Biomedical Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
|
|
Mar 13
|
Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2023 Earnings Call Transcript
|
|
Mar 13
|
Q4 2023 Clearside Biomedical Inc Earnings Call
|
|
Mar 12
|
Clearside Biomedical Inc (CLSD) Reports Significant Licensing Revenue Growth in Q4 and Full ...
|
|
Mar 12
|
Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
|
|
Mar 6
|
These 2 ‘Strong Buy’ Penny Stocks Could Surge Over 200%, Say Analysts
|
|
Feb 7
|
Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering
|